Clinical Characteristics of Peripheral Lymphocyte Subtypes in Chronic Active Epstein-Barr Virus Infection
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiad435 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Ang Wei und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Key Laboratory of Major Disease in…. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Herpesvirus 4, Human, CD8-Positive T-Lymphocytes, Killer Cells, Natural. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Municipal Science and Technology Commission, Beijing Hospitals Authority.
Abstract (Originalsprache)
Background
We aimed to analyze the clinical characteristics of peripheral Epstein-Barr virus (EBV)-infected lymphocyte subtypes in children with chronic active EBV infection (CAEBV).
Methods
The levels of peripheral EBV infection of CD4+ T cells, CD8+ T cells, and CD56+ natural killer (NK) cells were determined by flow cytometry and quantitative polymerase chain reaction (qPCR) in patients with CAEBV from July 2017 to July 2022.
Results
In total, 112 children with CAEBV were evaluated. Of these, CD4+ type, CD8+ type, and CD56+ type were defined in 44, 21, and 47 patients, respectively. Patients with CD8+ T-cell type had a significantly higher frequency of rash, while hepatomegaly was more common in patients with CD4+ T-cell type. Generally, patients with CD8+ T-cell type had the lowest overall survival rate (P = .017). Patients treated with chemotherapy and hematopoietic stem cell transplantation (HSCT) had a better prognosis (P = .001). In multivariate analysis, rash, hemophagocytic lymphohistiocytosis, CD8+ T-cell type, and no decrease of plasma EBV-DNA after treatment were independent indicators of poor prognosis (P = .002, .024, .022, and .012, respectively).
Conclusions
In children with CAEBV, rash was more frequent in patients with CD8+ T-cell type, whereas patients with CD4+ T-cell type were more likely to develop hepatomegaly. Patients with CD8+ T-cell type had a poor prognosis despite receiving chemotherapy or further HSCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Key Laboratory of Major Disease in Children, National Center for Children's Health, Ministry of Educatio…
- Hematologic Disease Laboratory, Beijing Pediatric Research Institute, Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, National Center for Children's Hea…
Förderung
- National Natural Science Foundation of China
- Beijing Municipal Science and Technology Commission
- Beijing Hospitals Authority
- National Science and Technology Key Projects
- Beijing Municipal Health Commission
Zitieren
APA
Wei, A., Ou, W., Zhao, Y., Ma, H., Zhang, L., Lian, H., Zhao, X., Zhang, Q., Wang, D., Li, Z., Wang, T., & Zhang, R. (2024). Clinical Characteristics of Peripheral Lymphocyte Subtypes in Chronic Active Epstein-Barr Virus Infection. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad435
Vancouver
Wei A, Ou W, Zhao Y, Ma H, Zhang L, Lian H, et al. Clinical Characteristics of Peripheral Lymphocyte Subtypes in Chronic Active Epstein-Barr Virus Infection. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad435
BibTeX
@article{Wei2024,
author = {Wei, Ang and Ou, Wenxin and Zhao, Yunze and Ma, Honghao and Zhang, Liping and Lian, Hongyun and Zhao, Xiaoxi and Zhang, Qing and Wang, Dong and Li, Zhigang and Wang, Tianyou and Zhang, Rui},
title = {Clinical Characteristics of Peripheral Lymphocyte Subtypes in Chronic Active Epstein-Barr Virus Infection},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiad435}
}
EUVIMED